TY - JOUR
KW - Adult
KW - Analgesics, Opioid/therapeutic use
KW - buprenorphine
KW - Buprenorphine/therapeutic use
KW - Drugs, Generic/therapeutic use
KW - Female
KW - generic
KW - Humans
KW - Male
KW - Opiate Substitution Treatment
KW - Opiate Substitution Treatment/psychology
KW - Opioid-Related Disorders/diagnosis/drug therapy/psychology
KW - Outpatients/psychology
KW - Patient Preference
KW - Prescription Drug Misuse
KW - Severity of Illness Index
KW - Young Adult
AU - P. Binder
AU - N. Messaadi
AU - M. C. Perault-Pochat
AU - S. Gagey
AU - Y. Brabant
AU - P. Ingrand
A1 - 
AB - As a form of opioid maintenance treatment, high-dose buprenorphine is increasingly being used in the United States. On the French market since 1996, it is the most commonly prescribed and frequently employed opioid maintenance treatment. For unknown reasons, the brand-name form is used far more often than the generic form (76-24%). The objective was to show that the patients' levels of addiction were differentiated according to the form of buprenorphine currently being used and to their previous experience of a different form. An observational study in 9 sites throughout France used self-assessment questionnaires filled out in retail pharmacies by all patients to whom their prescribed buprenorphine treatment was being delivered. The 151 canvassed pharmacies solicited 879 patients, of whom 724 completed the questionnaires. Participants were statistically similar to non-participants. The patients using the brand-name form subsequent to experience with the generic form exhibited a more elevated addiction severity index and a higher dosage than brand-name form users with no experience of a different form. Compared to generic users, their doses were higher, their was addiction more severe, and their alcohol consumption was more excessive; they were also more likely to make daily use of psychotropic substances. However, the level of misuse or illicit consumption was similar between these groups. Preferring the brand-name buprenorphine form to the generic form is associated with a higher level of severe addiction, a more frequent need for daily psychotropics, and excessive drinking; but the study was unable to show a causal link.
BT - Journal of addictive diseases
C5 - Opioids & Substance Use
CP - 2
CY - England
DO - 10.1080/10550887.2015.1136494
IS - 2
JF - Journal of addictive diseases
N2 - As a form of opioid maintenance treatment, high-dose buprenorphine is increasingly being used in the United States. On the French market since 1996, it is the most commonly prescribed and frequently employed opioid maintenance treatment. For unknown reasons, the brand-name form is used far more often than the generic form (76-24%). The objective was to show that the patients' levels of addiction were differentiated according to the form of buprenorphine currently being used and to their previous experience of a different form. An observational study in 9 sites throughout France used self-assessment questionnaires filled out in retail pharmacies by all patients to whom their prescribed buprenorphine treatment was being delivered. The 151 canvassed pharmacies solicited 879 patients, of whom 724 completed the questionnaires. Participants were statistically similar to non-participants. The patients using the brand-name form subsequent to experience with the generic form exhibited a more elevated addiction severity index and a higher dosage than brand-name form users with no experience of a different form. Compared to generic users, their doses were higher, their was addiction more severe, and their alcohol consumption was more excessive; they were also more likely to make daily use of psychotropic substances. However, the level of misuse or illicit consumption was similar between these groups. Preferring the brand-name buprenorphine form to the generic form is associated with a higher level of severe addiction, a more frequent need for daily psychotropics, and excessive drinking; but the study was unable to show a causal link.
PP - England
PY - 2016
SN - 1545-0848; 1055-0887
SP - 101
EP - 108
EP - 
T1 - Preference for brand-name buprenorphine is related to severity of addiction among outpatients in opioid maintenance treatment
T2 - Journal of addictive diseases
TI - Preference for brand-name buprenorphine is related to severity of addiction among outpatients in opioid maintenance treatment
U1 - Opioids & Substance Use
U2 - 26745033
U3 - 10.1080/10550887.2015.1136494
VL - 35
VO - 1545-0848; 1055-0887
Y1 - 2016
ER -